Drug Trial Radar · NCT04622345
Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies
Last checked: Nov 19, 2026Latest source record: Sep 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
47
Actual
Start
Nov 21, 2020
Primary completion
May 22, 2021
Study completion Jun 28, 2021
Sponsor
- Lead sponsor
- Vanda PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Nov 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of allergic conjunctivitis using an antigen challenge model
Conditions
- Allergic Conjunctivitis
Interventions
VSJ-110Drug
ophthalmic solution
PlaceboDrug
ophthalmic solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ocular Itching as Measured by Self-reported Numerical ScalesTime frame: 16 hours, 8 hours, and 15 minutes post-treatment
- Conjunctival Redness as Measured by Investigator Assessed Numerical ScalesTime frame: 16 hours, 8 hours, and 15 minutes post-treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Vanda Investigational Site
Andover, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.